The Puncturable Atrial Septal Defect Occluder Trial (the PASSER Trial)

Atrial Septal Defect Clinical Trial

Official title:

A Multicenter, Randomized, Parallel-controlled Clinical Trial to Evaluate the Efficacy and Safety of a New Atrial Septal Defect Occluder, ReAces®, and Delivery System for the Treatment of Atrial Septal Defect Occlusion

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05371366
• Other study ID #: HYYL2022-06ZC-01
• Status: Recruiting
• Phase: N/A
• Start date: April 22, 2022
• Est. completion date: April 22, 2023

Study information

• Verified date: May 2022
• Source: Shanghai Zhongshan Hospital
• Contact: Wenzhi Pan, Dr
• Phone: +86 13774475922
• Email: peden[@]sina.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A multicenter, randomized, parallel-controlled clinical trial to evaluate the efficacy and safety of a new atrial septal defect occluder, ReAces®, and delivery system for the treatment of atrial septal defect occlusion. Compared with the traditional atrial septal occluder, this new atrial septal occluder supports re-puncture after occluder implantation. Thus those patients who have undergone atrial septal defect closure with the novel device may be eligible for future radiofrequency ablation of atrial fibrillation or mitral valve intervention.

The trial is expected to enroll 128 patients who will be randomly assigned to the test group or control group in a 1:1 ratio. Patients in test group will received ReAces occluder，and the others the regular occluder.The experiment is scheduled to enroll 128 patients who will be randomly allocated to one of two groups: test or control. Patients in the test group will receive a ReAces occluder, while those in the control group will receive a standard occluder.The safety and efficacy of the two groups at 1 year after surgery will be compared.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 128
• Est. completion date: April 22, 2023
• Est. primary completion date: April 22, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. aged 18-70 years;

2. with congenital secundum atrial septal defect;

3. the maximal ASD diameter was =38 mm;

4. with atrial-level left-to-right shunt, with Qp/Qs shunt ratio =1.5:1, or TTE or clinical manifestations indicated the existence of defect that inducing overfilling of right atrium;

5. the distance from the margin of defect to coronary sinus, atrioventricular (AV) valve, and right superior pulmonary vein (RSPV) was =5 mm, according to the echocardiography measurements;

6. volunteered to participate in this study, and signed informed consents.

Exclusion Criteria:

1. ostium primordium ASD and sinus venosus ASD.

2. infective endocarditis and hemorrhagic disorders.

3. active thrombosis.

4. patients with severe pulmonary hypertension (mean pulmonary artery pressure measured by catheter > 30 mmHg) who are not taking targeted drugs

5. patients with a porous atrial septal defect that cannot be completely occluded by a single occluder.

6. with severe myocardial disorders or valvular disease not associated with ASD

7. infectious disease within the last 1 month, or uncontrolled infectious disease

8. bleeding disorders, untreated gastric or duodenal ulcers

9. thrombosis in left atrium

10. partial or total pulmonary vein ectopic drainage

11. left atrial septum, left atrial or left ventricular dysplasia

12. Patients whose size (too small for TEE probe, catheter size, etc.) or physical condition (active infection, etc.) makes them unsuitable for cardiac catheterization

13. Patients who are allergic to nickel

14. Patients with any contraindication to aspirin therapy (except for those able to take other antiplatelet agents for 6 consecutive months).

15. Pregnant or lactating women and those who plan to become pregnant during the trial

16. Patients with a life expectancy of <12 months or those who are unable to complete the study's prescribed follow-up schedule

17. Participation in another clinical trial of a drug or medical device within 30 days prior to screening.

18. Patients who have previously undergone surgical atrial septal defect repair or percutaneous interventional atrial septal defect closure.

19. Patients who, in the opinion of the investigator, are not suitable for participation in this study.

Related Conditions & MeSH terms

• Atrial Septal Defect
• Heart Septal Defects
• Heart Septal Defects, Atrial

Intervention

Device:
• ASD closure with the novel occluder (ReAces)
Transcatheter closure atrial septal defect with the novel occluder (ReAces)
• ASD closure with normal occluder
Transcatheter closure atrial septal defect with normal occluder

Locations

Country	Name	City	State
China	180 Fenglin Road	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Zhongshan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Successful rate of complete closure of atrial septal defect	The success rate of complete closure at 12 months after the procedure was used as the main efficacy index to evaluate the effectiveness of the novel atrial septal defect occluder ReAces, reflecting the long-term implantation effect of the device.	0-360 days
Secondary	Adverse events	all cause and cardiovascular mortality, pericardial tamponade, cerebrovascular events, malignant arrhythmia, infection, device migration, and occluder-related thrombosis or embolization during the operation or follow up.	0-360 days